From: Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer
Number | Percent | |
---|---|---|
Patient characteristics | ||
Age at treatment (yrs), median (range) | 69.2 | (46.4–86.8) |
Sex | ||
Female | 3 | 14.3 |
Male | 18 | 85.7 |
ECOG PS | ||
0–1 | 12 | 57.1 |
2 | 9 | 42.9 |
Pathology | ||
Squamous cell carcinoma | 21 | 100.0 |
Adenocarcinoma | 0 | 0.0 |
Site | ||
Upper thoracic (UI 20–25 cm) | 5 | 23.8 |
Middle thoracic (UI 25–30 cm) | 9 | 42.9 |
Lower thoracic (UI 30–40 cm) | 7 | 33.3 |
Stage | ||
I | 1 | 4.8 |
IIB | 4 | 19.0 |
IIIA | 3 | 14.3 |
IIIB | 7 | 33.3 |
IIIC | 6 | 28.6 |
Treatment characteristics | ||
Aim | ||
Definitive | 17 | 81.0 |
Preop | 4 | 19.0 |
Concurrent chemotherapy | 19 | 90.5 |
Chemotherapy regimen (n = 19) | ||
5-Fluorouracil+cisplatin | 18 | 94.7 |
5-Fluorouracil monotherapy | 1 | 5.3 |
RT modality | ||
IMRT | 21 | 100.0 |
3D-CRT | 0 | 0.0 |
Median total dose (Gy), median (range) | 63 | (44.1–69.3) |
Median fraction dose (Gy), median (range) | 2.1 | (1.8–2.1) |
Fractions of RT completed before mid-radiotherapy PET (fractions), median (range) | 11 | (9–12) |
Dose of RT completed before mid-radiotherapy PET (Gy), median (range) | 23.1 | (18.9–25.2) |